Long-term trends in HIV care entry: over 15 years of clinical experience from Poland.


Journal

HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392

Informations de publication

Date de publication:
10 2019
Historique:
accepted: 03 05 2019
pubmed: 30 6 2019
medline: 2 7 2020
entrez: 29 6 2019
Statut: ppublish

Résumé

Delay in HIV diagnosis and consequently late care entry with low CD4 counts remain a major challenge for the control of the HIV/AIDS epidemic. The aim of this study was to analyse the evolution of characteristics of the HIV epidemic in Poland. Cross-sectional data were collected for 3972 HIV-infected patients followed up in 14 of 17 Polish HIV treatment centres in the years 2000-2015. Clinical data were analysed and factors associated with late presentation (baseline CD4 count < 350 cells/μL or history of AIDS-defining illness) and advanced HIV disease (baseline CD4 count < 200 cells/μL or history of AIDS) were identified. The majority (57.6%) of patients entered care late, while 35.6% presented with advanced HIV disease. The odds of being linked to care late or with advanced HIV disease increased consistently across age categories, increasing from 2.55 [95% confidence interval (CI) 1.46-4.47] for late presentation and 3.13 (95% CI 1.49-6.58) for advanced disease for the 21-30-year-old category to 5.2 (95% CI 1.94-14.04) and 8.15 (95% CI 2.88-23.01), respectively, for individuals > 60 years of age. Increased risks of late entry and advanced HIV disease were also observed for injecting drug users [adjusted odds ratio (aOR) 1.74 (95% CI 1.16-2.60) and 1.55 (95% CI 1.05-2.30), respectively], with lower aOR associated with the men who have sex with men transmission route [aOR 0.3 (95% CI 0.31-0.59) and 0.39 (95% CI 0.29-0.53), respectively]. The frequencies of cases in which patients were linked to care late and with advanced HIV disease decreased over time from 67.6% (2000) to 53.5% (2015) (P < 0.0001) and from 43.5% (2000) to 28.4% (2015) (P = 0.001), respectively. Despite improvements over time, most patients diagnosed with HIV infection entered care late, with a third presenting with advanced HIV disease. Late care entry remains common among people who inject drugs and heterosexual groups.

Identifiants

pubmed: 31250958
doi: 10.1111/hiv.12762
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-590

Subventions

Organisme : Polish Scientific HIV Society
Pays : International

Informations de copyright

© 2019 British HIV Association.

Références

UNAIDS. Global HIV & AIDS statistics - 2018 fact sheet. Available at http://www.unaids.org/en/resources/documents/2018/unaids -data-2018 (accessed 04 Jan 2019).
Rosińska M. Cuurent trends I HIV/AIDS epidemiology in Poland 1999-2004. Euro Surveill 2006; 11: pii = 618.
Rosinska M, Janiec J, Niedźwiedzka-Stadnik M. Increase of new HIV diagnoses among men who have sex with men in Poland, 2000 to 2011. Euro Surveill 2013;18:pii. 20642..
Firląg-Burakacka E, Siwak E, Gizińska J, Swięcki P, Cielniak I, Horban A. Changes in trends of the HIV/AIDS epidemic based on surveillance data of Warsaw cohort. HIV/AIDS Rev 2009; 8: 12-15.
Parczewski M, Siwak E, Leszczyszyn-Pynka M et al. Meeting the WHO 90 target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristic. J Int AIDS Soc 2017; 20: 21847.
Pyziak-Kowalska K, Dusza M, Mularska E et al. Late presenters among newly diagnosed HIV-infected in Poland in 2006-2008. HIV/AIDS Rev 2017; 16: 244-250.
Wójcik-Cichy K, Jabłonowska O, Piekarska A et al. The high incidence of late presenters for HIV/AIDS infection in the Lodz province, Poland in the years 2009-2016: we are still far from the UNAIDS 90% target. AIDS Care 2018; 20: 1-4.
European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe 2017-2016 Data. Stockholm, ECDC, 2017.
Lucas SB, Curtis H, Johnson MA. National revive of death among HIV-infected adults. Clin Med 2008; 8: 250-252.
Morena S, Mocroft A, Monforte Ad. Medical and societal consequences of late presentation. Antivir Ther 2010; 15: 9-15.
Krentz HB, Gill MJ. The direct medical costs of late presentation (< 350/mm) of HIV infection over a 15-year period. AIDS Res Treat 2012; 2012: 757135.
Guaraldi G, Zona S, Menozzi M et al. Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. AIDS Res Ther 2017; 14: 8.
Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
Joint United Nations Programme on HIV/AIDS 90-90-90: An ambitious treatment target to help end the AIDS epidemic. 2014. Available at http://www.unaids.org/en/resources/documents/2014/90-90-90 (accessed 15 Dec 2018).
The late presenters working group in COHERE in EuroCoord. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill 2015;20:pii.30070.
ECDC. HIV testing. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2017 progress report. Available at https://ecdc.europa.eu/sites/portal/files/documents/HIV%20testing.pdf (accessed 5 Dec 2018).
Castro KG, Ward JW, Slutsker L, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 4: 11-19.
Antinori A, Coenen T, Costagiola D et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12: 61-64.
Darling KE, Hachfeld A, Cavassini M, Kirk O, Furrer H, Wandeler G. Late presentation to HIV are despite good access to health services: current epidemiological trends and how to do better. Swiss Med Wkly 2016; 146: w14348.
Wilson KA, Dray-Spira R, Aubrière C, Hamelin C, Spire B, Lert F, the ANRS-Vespa2 Study Group. Frequency and correlates of late presentation for HIV infection in France: older adults are a risk group - results from the ANRS-VESPA2 Study, France. AIDS Care 2014; 26: S83-S93.
Celesia BM, Castronuovo D, Pinzone MR et al. Late presentation of HIV infection: predictors of delayed diagnosis and survival in Eastern Sicily. Eur Rev Med Pharmacol Sci 2013; 17: 2218-2224.
Op de Coul EL, van Sighem A, Brinkman K. et al. Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort. BMJ Open 2016;6:e009688.
Chkhartishvilli N, Chokoshvili O, Bolokadze N et al. Late presentation of HIV infection in the country of Georgia: 2012-2015. PLoS ONE 2017; 12: e0186835.
Miranda C, Moneti A, Brogueira V et al. Evolution trends over three decades of HIV infection late diagnosis: the experience of a Portuguese cohort of 705 HIV infected patients. J Int AIDS Soc 2014; 17: 19688.
Mocroft A, Lundgren JD, Sabin ML et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013; 10: e1001510.
Elena Jipa R, Manea E, Benea S et al. Characteristic of late presenters in Bucharest. J Int AIDS Soc 2014; 17: 19691.
Leutscher PD, Laursen T, Andersen B et al. HIV late presenters in Denmark: need for increased diagnostic awareness among general practitioners. Dan Med Bull 2011; 58: 4253-4257.
Smith RD, Delpech VC, Brown AE et al. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010; 24: 2109-2115.
de Olalla PG, Mazardo C, Sambeat MAHIV et al. Surveillance Group. Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. AIDS Res Ther 2011; 8: 22.
Borghi V, Girardi E, Bellelli S et al. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008; 49: 282-286.
Darcis G, Lambert I, Sauvage AS et al. Factors associates with late presentation for HIV care in single Belgian reference center: 2006-2017. Sci Rep 2018; 8: 8594.
Chmielewska I, Dobroczek G, Panuciak A. Obywatele Ukrainy pracujący w Polsce-raport z badania. Warszawa, Departament Statystyki NBP, 2018. Available at https://www.nbp.pl/aktualnosci/wiadomosci_2018/obywatele-Ukrainy-pracujacy-w-Polsce-raport.pdf (accessed 10 Dec 2018).
European Centre for Disease Prevention and Control. HIV and AIDS In: ECDC. Annual epidemiological report for 2016. Stockholm, ECDC, 2018.
Parczewski M, Leszczyszyn-Pynka M, Witak-Jędra M et al. Expanding HIV-1 subtype B transmission networks among men who have sex with men in Poland. PLoS ONE 2017; 12: e0172473.
Cainrs G, McCormack S, Molina JM. The European preexposure prophylaxis revolution. Curr Opin HIV AIDS 2016; 11: 74-79.
Kowalska JD, Shepherd L, Ankiersztejn-Bartczak M et al. Poor linkage to care despite significant improvement in access to early cART in central Poland - data from test and keep in care (TAK) Project. PLoS ONE 2016; 11: e0162739.
Ankiersztejn-Bartczak M, Firląg-Burkacka E, Czeszko-Paprocka H et al. Factors responsible for incomplete linkage to care after HIV diagnosis: preliminary results from the Test and Keep in Care (TAK) project. HIV Med 2015; 16: 88-94.
Rosińska M, Simmons R, Marzec-Bogusławska A, Janiec J, Porter K. Relating HIV testing patterns in Poland to risky and protective behaviour. AIDS Care 2016; 28: 423-431.

Auteurs

E Siwak (E)

Hospital for Infectious Diseases, HIV Out-Patient's Clinic, Warsaw, Poland.

A Horban (A)

Hospital for Infectious Diseases, HIV Out-Patient's Clinic, Warsaw, Poland.
Department for Adults Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.

M Witak-Jędra (M)

Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland.

I Cielniak (I)

Hospital for Infectious Diseases, HIV Out-Patient's Clinic, Warsaw, Poland.

E Firląg-Burkacka (E)

Hospital for Infectious Diseases, HIV Out-Patient's Clinic, Warsaw, Poland.

M Leszczyszyn-Pynka (M)

Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland.

A Witor (A)

Regional Hospital, Out-Patient's Clinic for Immune Deficiency, Chorzów, Poland.

K Muller (K)

Regional Hospital, Out-Patient's Clinic for Immune Deficiency, Chorzów, Poland.

M Bociąga-Jasik (M)

Department of Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland.

A Kalinowska-Nowak (A)

Department of Infectious Diseases, Jagiellonian University Medical College, Kraków, Poland.

J Gąsiorowski (J)

Department of Infectious Diseases, Hepatology and Acquired Immune Deficiencies, Wroclaw Medical University, Wrocław, Poland.

B Szetela (B)

Department of Infectious Diseases, Hepatology and Acquired Immune Deficiencies, Wroclaw Medical University, Wrocław, Poland.

E Jabłonowska (E)

Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland.

K Wójcik-Cichy (K)

Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland.

J Jankowska (J)

Pomeranian Center of Infectious Diseases and Tuberculosis in Gdańsk, HIV Outpatient Clinic, Gdańsk, Poland.

M Lemańska (M)

Pomeranian Center of Infectious Diseases and Tuberculosis in Gdańsk, HIV Outpatient Clinic, Gdańsk, Poland.

A Olczak (A)

Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.

E Grąbczewska (E)

Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.

A Grzeszczuk (A)

Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.

M Rogalska-Plonska (M)

Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.

M Suchacz (M)

Department of Infectious and Tropical Diseases and Hepatology, Medical University in Warsaw, Warsaw, Poland.

T Mikuła (T)

Department of Infectious and Tropical Diseases and Hepatology, Medical University in Warsaw, Warsaw, Poland.

W Łojewski (W)

Department of Infectious Diseases, Regional Hospital in Zielona Góra, Zielona Góra, Poland.

D Bielec (D)

Department of Infectious Diseases, Medical University in Lublin, Lublin, Poland.

P Kocbach (P)

Clinical Ward of Infectious Diseases, Collegium Medicum University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.

W Błudzin (W)

Department of Infectious Diseases, Regional Hospital in Opole, Opole, Poland.

M Parczewski (M)

Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH